Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
Jolien M. Bueno-de-Mesquita(The Netherlands Cancer Institute), Sabine C. Linn(Oncode Institute), Laura van ‘t Veer, Emiel J. Rutgers(Oncode Institute), Jelle Wesseling(Leiden University Medical Center), Rudi M. H. Roumen(Radboud University Nijmegen), Harm van Tinteren(Princess Máxima Center), Kim Karsenberg(The Netherlands Cancer Institute), Guido Brink(Agendia (Netherlands)), Douwe E. Atsma(The Netherlands Cancer Institute), Tin S Wu(The Netherlands Cancer Institute), Annuska M. Glas(Leiden University Medical Center), Marc J. van de Vijver(The Netherlands Cancer Institute), Wim H. van Harten(The Netherlands Cancer Institute), Valesca P. Retèl(The Netherlands Cancer Institute), Kirsten FL Douma(The Netherlands Cancer Institute), Frits SAM van Dam(The Netherlands Cancer Institute), Johannes L. Peterse(The Netherlands Cancer Institute), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Arno Floore(Agendia (Netherlands)), C. van Krimpen(Reinier de Graaf Hospital), Frank E. Bellot(Spaarne Ziekenhuis)
Cited by 278
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k